Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
08 February 2023 - 8:00AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it will release financial and
operational results for fourth quarter and full year 2023 on
Tuesday, February 28, 2023, before markets open. Aurinia’s
management team will host a conference call/webcast at 8:30 am ET
that day to review these results and provide a general business
update. Interested participants can dial 877-407-9170
(Toll-free U.S. & Canada). The audio webcast can also be
accessed under "News/Events” through the “Investors” section of the
Aurinia corporate website at www.auriniapharma.com. A replay of the
audio webcast will be available on Aurinia’s website.
About Aurinia Aurinia Pharmaceuticals is a fully
integrated biopharmaceutical company focused on delivering
therapies to treat targeted patient populations that are impacted
by serious diseases with a high unmet medical need. In January
2021, the Company introduced LUPKYNIS® (voclosporin), the first
FDA-approved oral therapy for the treatment of adult patients with
active lupus nephritis (LN). The Company’s head office is in
Victoria, British Columbia, its U.S. commercial hub is in
Rockville, Maryland, and the Company focuses its development
efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230207006027/en/
Aurinia@westwicke.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024